MA-ULTIVUE
19.8.2021 15:04:13 CEST | Business Wire | Press release
Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation.
Fenel Eloi is a highly seasoned life sciences executive experienced in leading the transformation of small and mid-size companies to large operating global organizations. Mr. Eloi served as the CFO and then COO at Cell Signaling Technology, a bio-reagents company, from 2005 to 2018, where he provided leadership in the transformation of the company to a global operation. He currently serves on the Board of Directors and chairs the audit committee of 908 Devices, Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis. He also serves on the board of directors of MitoTherapeutix, a privately held drug development biotech company.
“I am very excited to join Ultivue and help them scale their operations to the next level. This is an exciting time for spatial biology and Ultivue has a great opportunity to rapidly grow and favorably impact both their customers’ search for improved cancer treatments and patients’ lives,” said Mr. Eloi.
Mary Pat Lancelotta is currently Vice President, Corporate Marketing and Communications at Adaptive Biotechnologies (Nasdaq: ADPT), a pioneer and leader in immune medicine. She is a seasoned healthcare strategist with a passion for precision medicine and brings over 20 years of business and strategy experience. Prior to Adaptive, Mary Pat led corporate and Product Marketing for Foundation Medicine, a molecular information company. Before joining Foundation Medicine, she led corporate strategic initiatives and strategic planning at Quest Diagnostics. Mary Pat holds an MBA with honors from Columbia Business School and a BS in Biochemistry from Boston College. She is also on the board of directors of Molecular Match, a clinical decision support company, and the TargetCancer Foundation.
“I am delighted to join the Board of Ultivue and look forward to working with the management team and fellow Board members to help grow the business, especially in the area of artificial intelligence to support image analysis,” said Mary Pat Lancelotta. “As we look to the future, working with big pharma, CRO and academic medical center customers, Ultivue has a tremendous opportunity to expand the impact of spatial biology on patients’ lives.”
“It’s an exciting time at Ultivue,” noted Jacques Corriveau, President and CEO. “The combination of Mary Pat’s ability to drive innovative commercial strategy for a global market alongside Fenel’s experience enabling technology advancements within our partnership ecosystem will help our customers bring exciting new therapies to market and positively impact the drive toward personalized cancer treatment.”
About Ultivue
Ultivue, Inc. provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. For more information, visit ultivue.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 13:58:00 CET | Press release
Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu
Futur Delivers Strong Growth and Record Profit in 202520.3.2026 12:05:00 CET | Press release
In 2025, Futur added 21,000 new customers and the inflows amounted to 34 billion kronor. At the end of the year, the total savings capital was 252 billion kronor, an increase of 7% from the previous year and a new record level. "2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how a
Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 12:00:00 CET | Press release
Lyten announces the establishment of its next Lyten Industrial Hub in Gdańsk, Poland. The hub will bring together key manufacturing and digital resources to support energy infrastructure, the development of artificial intelligence, and the defense sector. In February 2026, Lyten announced the creation of the first Lyten Industrial Hub in Sweden, combining battery production operations there with a 1 GW AI data center campus. Lyten plans to complete its feasibility study by the end of 2026 to determine the full development plan Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center
PUMA Reveals Its Most Powerful International Football Kit Lineup yet on the Streets of New York City20.3.2026 08:00:00 CET | Press release
Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most prominent African partner federations of any brand in the tournament, in a community-first celebration of football, music, and culture in New York City Global sports company PUMA unveiled its new national team kits for 11 nations with a street-level event at Domino Square in New York City, that placed football, music, food, and culture at the center stage in a celebration of the game. Rather than launching in a stadium setting or in a cinematic brand film, PUMA chose to reveal the kits in play, worn first by local community players from each nation on the streets of New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320641449/en/ Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom